Dr Martens /£DOCS
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Dr Martens
Dr. Martens, also known as Docs or DMs, is a United Kingdom-based company renowned for its iconic range of footwear, alongside a variety of clothing and accessories. The company, headquartered in Wollaston, Northamptonshire, operates primarily in the footwear manufacturing sector. Established in 1947, Dr. Martens has grown to become a symbol of self-expression and counterculture, distributing its products worldwide under the Dr. Martens brand.
Ticker
£DOCS
Sector
Primary listing
LSE
Employees
2,348
Headquarters
Website
Dr Martens Metrics
BasicAdvanced
£876M
192.90
£0.00
0.15
£0.02
2.04%
Price and volume
Market cap
£876M
Beta
0.15
52-week high
£0.95
52-week low
£0.43
Average daily volume
972K
Dividend rate
£0.02
Financial strength
Current ratio
2.591
Quick ratio
1.368
Long term debt to equity
97.107
Total debt to equity
110.289
Dividend payout ratio (TTM)
211.11%
Interest coverage (TTM)
2.01%
Profitability
EBITDA (TTM)
75.7
Gross margin (TTM)
64.97%
Net profit margin (TTM)
0.57%
Operating margin (TTM)
7.71%
Effective tax rate (TTM)
48.86%
Revenue per employee (TTM)
£340,000
Management effectiveness
Return on assets (TTM)
4.12%
Return on equity (TTM)
1.23%
Valuation
Price to earnings (TTM)
192.9
Price to revenue (TTM)
1.102
Price to book
2.39
Price to tangible book (TTM)
9.46
Price to free cash flow (TTM)
4.887
Free cash flow yield (TTM)
20.46%
Free cash flow per share (TTM)
0.185
Dividend yield (TTM)
2.04%
Growth
Revenue change (TTM)
-10.20%
Earnings per share change (TTM)
-93.32%
3-year revenue growth (CAGR)
-4.64%
10-year revenue growth (CAGR)
12.84%
3-year earnings per share growth (CAGR)
-70.44%
10-year earnings per share growth (CAGR)
36.65%
3-year dividend per share growth (CAGR)
-22.60%
What the Analysts think about Dr Martens
Analyst ratings (Buy, Hold, Sell) for Dr Martens stock.
Bulls say / Bears say
Dr Martens forecasts a return to profit growth in fiscal 2026 with adjusted pre-tax profit expected between £54 million and £74 million, up from £34.1 million in FY25. (Reuters)
Online sales of shoes, mules, and sandals grew in the 2025 financial year, demonstrating successful diversification of Dr Martens' product portfolio beyond its traditional boot offerings. (Reuters)
The company shifted 62% of its autumn/winter production to Vietnam and 31% to Laos, bolstering supply chain resilience and mitigating exposure to potential tariffs on Chinese-made goods. (Reuters)
Adjusted pre-tax profit of £34.1 million in FY25 marked the third consecutive annual profit decline, highlighting sustained earnings pressure. (Reuters)
Sales of the company's core boot products declined in FY25, even as online sales of shoes, mules, and sandals grew, underscoring ongoing weakness in its flagship category. (Reuters)
Revenue from the Americas fell 11% for the year ended March 30, 2025, reflecting persistent headwinds in its largest market. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Dr Martens Financial Performance
Revenues and expenses
Dr Martens Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
Oct8
Dr Martens
DividendPayment
£0.017Per share
FAQs
What’s the current market cap for Dr Martens stock?
Dr Martens (DOCS) has a market cap of £876M as of September 14, 2025.
What is the P/E ratio for Dr Martens stock?
The price to earnings (P/E) ratio for Dr Martens (DOCS) stock is 192.9 as of September 14, 2025.
Does Dr Martens stock pay dividends?
Yes, the Dr Martens (DOCS) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is £0.0184 and the yield is 2.04%. Dr Martens has a payout ratio of 211.11% on a trailing twelve-month basis.
When is the next Dr Martens dividend payment date?
The next Dr Martens (DOCS) dividend payment is scheduled for October 08, 2025.
What is the beta indicator for Dr Martens ?
Dr Martens (DOCS) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.